US2012172422A1PendingUtilityA1
Methods of Treatment Using a Prodrug of an Excitatory Amino Acid
Est. expiryJun 11, 2022(expired)· nominal 20-yr term from priority
Inventors:Eric David MoherJames Allen MonnConcepcion Pedregal-TerceroJaime Gonzalo Blanco-UrgoitiIvan Collado Cano
A61P 31/18A61P 3/10A61P 9/10A61P 43/00A61P 29/00A61P 25/24A61P 25/08A61P 25/14A61P 25/36A61P 25/16A61P 25/20A61P 25/06A61P 25/32A61P 25/34A61P 27/02A61P 25/30A61P 25/18A61P 25/22A61P 25/28A61P 25/04A61P 25/00A61P 13/02A61P 21/04A61P 19/00A61P 21/00A61P 1/08C07D 333/78A61K 47/555A61K 38/05A61K 47/542C07C 2602/18C07K 5/06026C07C 237/12A61K 47/54C07K 1/00
45
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
This invention relates to synthetic excitatory amino acid prodrugs and processes for their preparation. The invention further relates to methods of using, and pharmaceutical compositions comprising, the compounds for the treatment of neurological disorders and psychiatric disorders.
Claims
exact text as granted — not AI-modified1 - 27 . (canceled)
28 . A method for treating a neurological disorder which is chronic pain in a patient which comprises administering to the patient in need of treatment thereof a pharmaceutically-effective amount of (1R,4S,5S,6S)-4-(2′S-4′-methylthio-2′- aminobutanonyl)amino-2,2-dioxo-2λ 6 -thia-bicyclo[3.1.0]hexane-4,6-dicarboxylic acid or a pharmaceutically acceptable salt thereof wherein treating is the restraining slowing, stopping, or reversing of a resultant symptom.
29 . A method for treating a neurological disorder which is chronic pain in a patient which comprises administering to the patient in need of treatment thereof a pharmaceutically-effective amount of (1R,4S,5S,6S)-4-(2′S,-4′-methylthio-2′- aminobutanonyl)amino-2,2-dioxo-2λ 6 -thia-bicyclo[3.1.0]hexane-4,6-dicarboxylic acid monohydrate wherein treating is the restraining slowing, stopping, or reversing of a resultant symptom.
30 . A method for treating a psychiatric disorder which is bipolar disorders or psychosis in a patient which comprises administering to the patient in need of treatment thereof a pharmaceutically-effective amount of (1R,4S,5S,6S)-4-(2′S-4′-methylthio-2′- aminobutanonyl)amino-2,2-dioxo-2λ 6 -thia-bicyclo[3.1.0]hexane-4,6-dicarboxylic acid or a pharmaceutically acceptable salt thereof wherein treating is the restraining slowing, stopping, or reversing of a resultant symptom.
31 . A method for treating a psychiatric disorder which is bipolar disorders or psychosis in a patient which comprises administering to the patient in need of treatment thereof a pharmaceutically-effective amount of (1R,4S,5S,6S)-4-(2′S-4′-methylthio-2′- aminobutanonyl)amino-2,2-dioxo-2λ 6 -thia-bicyclo[3.1.0]hexane-4,6-dicarboxylic acid monohydrate wherein treating is the restraining, slowing, stopping, or reversing of a resultant symptom.Join the waitlist — get patent alerts
Track US2012172422A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.